FindTrial
Sign In

LY2963016

DRUG11 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HealthyHealthy VolunteersType 1 DiabetesType 2 Diabetes

Phase 1

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
CompletedNCT01374178
Eli Lilly and CompanyDiabetes Mellitus
Start: 2011-06-30End: 2011-07-31Updated: 2014-10-07
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
CompletedNCT01476345
Eli Lilly and CompanyDiabetes Mellitus
Start: 2011-11-30End: 2012-07-31Updated: 2014-10-07
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
CompletedNCT01600950
Eli Lilly and CompanyDiabetes Mellitus, Type 1
Start: 2012-05-31End: 2012-07-31Updated: 2014-10-07
A Study of LY2963016 in Healthy Participants
CompletedNCT01634165
Eli Lilly and CompanyHealthy Volunteers
Start: 2012-07-31End: 2012-09-30Updated: 2014-10-07
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
CompletedNCT01688635
Eli Lilly and CompanyHealthy
Start: 2012-09-30End: 2013-02-28Updated: 2014-10-07
A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants
CompletedNCT02955953
Eli Lilly and CompanyHealthy
Start: 2016-11-14End: 2017-01-04Updated: 2017-03-21

Phase 3

A Study in Adults With Type 2 Diabetes
CompletedNCT01421459
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2011-09-30End: 2012-09-30Updated: 2014-12-18
A Study in Adults With Type 1 Diabetes
CompletedNCT01421147
Eli Lilly and CompanyDiabetes Mellitus, Type 1
Start: 2011-08-31End: 2013-04-30Updated: 2014-10-09
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
CompletedNCT02302716
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2014-12-31End: 2016-07-31Updated: 2017-10-24
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
CompletedNCT03338023
Eli Lilly and CompanyType 1 Diabetes
Start: 2018-03-23End: 2020-03-05Updated: 2021-03-29
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
CompletedNCT03338010
Eli Lilly and CompanyType 2 Diabetes
Start: 2018-03-22End: 2020-03-18Updated: 2021-05-25

Related Papers

Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus<sup>®</sup>): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial.
2022-04-262 citations
Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study
Clinical Drug Investigation2019-05-222 citations
Lilly Insulin Glargine Versus Lantus<sup>®</sup> in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5).
2019-01-0214 citations
Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus<sup>®</sup> Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation.
2018-05-315 citations
Similar Efficacy and Safety of Basaglar<sup>®</sup> and Lantus<sup>®</sup> in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study.
2018-03-145 citations
How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014
Figshare2014-01-01